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Introduction
Each year, over 220,000 [1,2] women in the United States are 
diagnosed with breast cancer; of these more than 12,000 are Florida 
residents [2,3]. While there are clear genetic risk factors for breast 
cancer, only 5-10% of all cases are thought to be hereditary [4]. A 
previous cancer diagnosis, physical inactivity, and obesity are associated 
with increased breast cancer risk and mortality; with obesity alone 
accounting for 30% of all breast cancer cases [5-7]. In fact, adipocytes 
in the breast tissue are essential for breast tumor development and 
progression [8]. Accordingly, survivorship is higher among women 
with a healthy weight [BMI 18-24.9 kg/m2] at diagnosis compared to 
overweight or obese women [9]. Weight gain post-diagnosis may be 
associated with increased risk of cancer-related death [10,11]. Breast 
cancer survivors are at increased mortality risk from non-cancer causes 
such as cardiovascular disease, type 2 diabetes, and other chronic 
conditions compared with women never diagnosed and treated for 
cancer [12-14]. 
While some patients diagnosed with cancer make improvements in 
their dietary habits, most are no more likely to maintain these changes 
than the general population [15,16]. The American Cancer Society 
recommends adopting a healthy lifestyle including weight loss if 
overweight, consuming a healthy diet, and increasing physical activity 
as protective behaviors for cancer survival and recurrence prevention 
[17]. Although these are the recommendations, the effect of weight 
loss and the long-term maintenance of weight loss on breast cancer 
recurrence and/or survival after diagnosis are not known. Given the 
impact of weight status and physical inactivity on breast cancer risk, 
Abstract
Breast cancer risk, and risk of associated co-morbidities such as cardiovascular disease, is highest among overweight 
or obese women with a previous history of breast cancer. The objective of this study is to test the effectiveness of a 
tailored nutrition, physical activity, and behavioral weight management intervention for breast cancer survivors against 
a widely available commercial weight management program. We hypothesize that an intervention tailored to the 
unique psychological, nutritional, and physical needs of breast cancer survivors will provide superior physiological and 
psychological benefits compared to an existing commercial program for the general population. To test our hypothesis, 
we initially conducted a focus group with both breast cancer survivors and oncology affiliated health care providers in 
order to illicit feedback to develop an intervention customized specifically to breast cancer survivors. Subsequently, in 
a randomized, multicenter trial, we are studying the effect of the tailored program on overweight/obese women (N=120) 
with a history of breast cancer (3 months to 5 years post-primary treatment) on body weight and composition, markers 
of systemic inflammation related to cancer and associated chronic diseases, physical activity habits, dietary intake, 
health-related quality of life, and program adherence and satisfaction. Assessments will be taken prior to study initiation 
immediately following the intervention and at 6 months post-intervention to assess long-term maintenance of weight, 
lifestyle behaviors, and impact on physiological markers of disease risk. This project is unique in that it addresses weight 
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a recent review article calls for a clinical intervention to evaluate 
together the impact that fat loss and increasing physical activity 
will have on breast cancer progression [18]. Since women who 
are overweight/obese at diagnosis or who gain weight post-cancer 
diagnosis are at an increased risk for breast cancer recurrence, 
as well as increased morbidity and mortality, we predict that 
implementation of a successful weight management intervention 
for breast cancer survivors may have even greater benefits than for 
individuals in the general overweight/obese population. 
This study is a randomized, behavioral lifestyle intervention 
for female breast cancer survivors. Specifically, the intervention is 
3-months with a 6-month follow up to evaluate the effectiveness of a 
tailored lifestyle intervention designed to promote sustained weight 
loss and increased physical activity in an important and understudied 
population – overweight and obese breast cancers survivors, post-
cancer treatment.
Objectives
This pilot study is funded through the University of Florida and will 
be conducted at both the University of Florida and at the University 
of North Florida. The study is approved by the Institutional Review 
Boards at each university. The primary aim of the study is to compare 
the impact of a Tailored Lifestyle Intervention (TLI) and a Commercial 
Weight Loss Program (CWLP) on weight change at post-intervention 
and long-term follow-up in a sample of overweight/obese female breast 
cancer survivors. The secondary aims are to compare the impact of 
the interventions at post intervention and long-term follow up on 1) 
changes in inflammation/chronic disease markers and 2) changes in 
health related quality of life and self-efficacy within this population. 
The study will be carried out in two phases: 1) focus groups to inform 
the TLI components, and 2) a randomized trial to compare the efficacy 
of TLI versus CWLP. 
Methods
Phase 1: Focus groups to inform the Tailored Lifestyle 
Intervention (TLI): Focus groups will be conducted in both 
geographic locations to elicit input on topics and design of the TLI 
prior to beginning recruitment for the intervention. Two different 
populations will be recruited for the focus groups: breast cancer 
survivors and health care providers that are integral to the survivors’ 
care including, but not limited to: social workers, physical therapists, 
registered dietitians, oncologists and breast surgeons. Each focus group 
will be led by either a trained research assistant or an investigator by 
asking probing questions meant to elicit feedback on different aspects 
of a behavioral intervention specifically tailored for breast cancer 
survivors. Topics for discussion for health care providers will include 
barriers to physical activity and proper nutrition as they relate to weight 
management for their breast cancer patients. Breast cancer survivors 
will be asked questions regarding beliefs on barriers and motivators 
of healthy lifestyle behaviors; the impact of family, friends, and health 
care providers on weight loss intentions and behaviors; and specific 
concerns about nutrition and physical activity as they relate to breast 
cancer survivorship. Each focus group will be asked about the pertinent 
components to designing a tailored weight loss program specifically for 
breast cancer survivors. Each focus group discussion will be recorded 
and transcribed for further content analysis by multiple members of 
the research team. Once a consensus is reached of the pertinent topics 
from each focus group, the collected data will be used in the design of 
the TLI group.
Phase 2: Randomized trial to compare the Tailored Lifestyle 
Intervention to Weight Watchers: Individuals interested in 
participating in the randomized trial will call the Clinical Nutrition Lab 
at the University of Florida to complete a telephone screen interview. 
If they meet the initial study criteria, they will then be scheduled for 
an in-person screening assessment in order to determine their final 
eligibility for the study. If eligible, participants will attend a second 
visit where they will complete the initial study assessments (body 
composition, waist circumference, sagittal abdominal diameter, and 
several questionnaires), and receive their randomization assignment. 
Up to 120 eligible participants (up to 60 at the University of Florida 
in Gainesville and up to 60 at the University of North Florida in 
Jacksonville) will be randomized for inclusion in the study. These 
participants will be randomized to either the weekly group TLI (led 
by a registered dietitian) or to a CWLP (Weight Watchers). The 
intervention period for both groups is 3 months and will be offered to 
the participants at no cost. Randomization stratification will include 
BMI category and breast cancer stage. In order to create balanced 
groups, randomization will occur at the site level. Immediately 
following the 3 month intervention period, participants will undergo 
follow-up assessments to determine long-term physiological and 
behavioral changes. Similar assessments will occur for all participants 6 
months after the intervention conclusion. Data analysis and reporting 
will begin immediately following this final assessment period. 
Dietetic practice based research network (DPBRN)
A unique aspect of this study is that the Registered Dietitian 
Nutritionists (RDN) hired to lead the TLI groups will be chosen from 
the DPBRN. This group is an initiative of the Academy of Nutrition 
and Dietetics that consists of RDNs across the country in various 
clinical, community, and private practice settings that are interested in 
research. Practice Based Research Networks (PBRNs) serve two major 
roles; providing a framework for testing the effectiveness of previous 
well-controlled clinical trials in real world settings and furnishing a 
mechanism to speed the translation of research findings into clinical 
practice. Previous successful weight management trials, like the Diabetes 
Prevention Program and the Look AHEAD Study have been conducted 
in large metropolitan areas with substantial resources and highly 
trained interventionists [19,20]. Previous community based trials in 
clinical settings have demonstrated that research conducted in a highly 
controlled setting does not necessarily have the same effectiveness 
in a community setting [21]. Testing both the effectiveness and the 
process of delivering a behavioral weight management intervention in 
a community setting where the intervention is led by interventionists, 
here RDNs, outside of a large academic center, with patients with a 
history of chronic disease is imperative. 
The RDNs for this study will be recruited through the DPBRN’s 
listserv. Interested candidates will be provided with information about 
the study and then interviewed through a formal process to determine 
both practicality of delivering the intervention within their current work 
and life situation as well as their aptitude for the project. Interviews 
will be conducted over the telephone. Candidate RDNs will be asked 
to role play in a counseling situation as well as respond to various 
clinical situations to determine their aptitude for using motivational 
interviewing techniques. Once selected, RDNs will attend a one-day 
training that will review the study protocol, intervention materials, and 
allow time for reviewing and practicing motivational interviewing and 
group facilitation skills. The success of this design will also serve as a 
pilot model for conducting similar studies on a larger geographic scale. 
Participants: Participants will include up to 120 overweight/obese 
women (BMI>27; aged 21-65) with a previous diagnosis of breast 
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cancer stages 1-3. All participants must be in breast cancer remission 
for 3 months to 5 years and must receive written medical clearance 
from their primary care or current oncology physician to enroll in the 
study. Participants who experience medical complications during the 
intervention will be withdrawn from the study.
Recruitment: Participants will be recruited primarily through the 
placement of posters, flyers, and brochures at oncology and radiology 
practices in Gainesville and Jacksonville. Flyers will also be posted at 
community health events, local cancer societies and through radio and 
newspaper advertising. Individuals’ willingness to participate in the 
study will in no way affect their medical treatment. 
Inclusion criteria 
Participants included in the study will meet the following inclusion 
criteria: 1) female, 2) age 21-65, 3) BMI of 27-45 kg/m2, 4) history of 
stage 1, 2, or 3 breast cancer, and 5) have completed primary treatments 
(chemotherapy, radiation, and/or surgical treatment) for breast cancer 
(with or without maintenance therapy) within the last 3 months to 5 
years. Participants will be required to provided consent and have a letter 
of approval to participate from their physician. Participants must be 
willing/able to attend group meetings and assessments in Gainesville or 
Jacksonville and have been weight stable, (i.e. not lost/gained ≥ 10 net 
lbs.) in the preceding 6 months, or since the end of primary treatment, 
whichever is more recent.
Exclusion criteria 
Participants will be excluded from the study if they report a condition 
likely to influence treatment outcomes, their ability to participate in 
the treatment protocol, or for which the eating and physical activity 
behavior changes are contraindicated, including: history of bariatric 
surgery, pregnant, lactating, or planning on becoming pregnant in next 
24 months, serious/chronic infectious disease, chronic malabsorption 
syndrome, chronic liver disease, chronic pancreatitis, current irritable 
bowel syndrome, congestive heart failure, uncontrolled angina within 
the past 6 months, history of musculoskeletal or chronic lung diseases 
that limit physical activity, uncontrolled or insulin-dependent diabetes, 
and/or uncontrolled hypertension. Participants also are excluded if 
they received cancer treatment within the past 5 years (other than 
for breast cancer) or have any other physical condition (other 
than history of breast cancer) deemed likely to limit 5-year life 
expectancy or significantly interfere with individuals’ ability to 
participate in a lifestyle intervention involving eating and physical 
activity changes. Participants also are excluded if they are taking 
antipsychotic medications, monoamine oxidase inhibitors, systemic 
corticosteroids, chemotherapeutics medications, or weight-loss 
medications. Additional exclusion criteria include significant 
psychiatric disorder, illicit drug use or excessive use of alcohol, 
current participation in Weight Watchers or any other weight loss 
program or another research study; inability to read English at the 
5th grade level, inability/unwillingness to provide informed consent 
or unwillingness to receive random assignment to TLI or CWLP.
Intervention Groups
Tailored lifestyle intervention (TLI)
The TLI will be a 3-month weight management program tailored 
to the specific needs of women in remission from breast cancer based 
on the data collected from focus groups. This duration was selected to 
match a 3-month Weight Watchers membership and as an effective 
period to observe a reduction in weight loss. While sessions will include 
standard topics such as self- monitoring, increasing physical activity, 
healthy eating, problem solving, and building social support, these 
sessions will be specifically tailored to women who have had breast 
cancer and various treatments. Groups will consist of 10-15 participants 
and will be led by a RDN recruited and selected from the DPBRN. All 
group leaders will participate in a motivational interviewing training 
session so that the intervention is effective in the manner in which it 
was designed. Participants will be remunerated for taking part of the 3 
month and 6 month follow up assessments. Initially, individual sessions 
will occur followed by 12 weeks of group sessions. During the weekly 
sessions, the RDN will use group motivational interviewing techniques 
when appropriate to strengthen participants’ motivation for improving 
their nutrition and activity behaviors to promote sustained weight 
loss. Participants will self-select foods, as opposed to utilizing meal 
replacements or a “prescribed” meal plan, with the goal of reducing 
energy intake to promote a 1-2 pound weight loss per week. Emphasis 
will be placed on following a Dietary Approaches to Stop Hypertension 
(DASH) eating style with an emphasis on fruits, vegetables, nuts, 
legumes and seafood. Participants will set weekly goals that will be built 
upon throughout the program. 
Community weight loss program (CWLP)
The CWLP group will receive a 3-month commercial weight 
loss program (i.e., Weight Watchers) at no cost. During the active 
phase of the study, these individuals will be encouraged to attend the 
weekly meetings at their local weight watchers center and also have 
online access to the program. The 3-month membership during the 
active study period will be paid by the study, whereas longer-term 
participation will be at the cost of the participant. CWLP participants 
will not be prohibited from continuing to attend Weight Watchers 
during the 6-month follow-up period. 
Assessment and Outcome Measures: Measurements are taken 
at the screening visit, randomization/baseline, post-intervention, 
and follow-up assessment visits. The following is a description of the 
measures that will be collected at each visit, and Table 1 displays the 
time points at which these measures will be collected (Tables 1 and 2).
Statistical Analysis
The number of participants required for this study was determined 
from data in the literature and our own experiences with weight 
management interventions; we expect a decrease in body weight of 
approximately 5-10% from baseline to week 13. A sample size of 102 
will be sufficient to detect a 5% difference in weight between the two 
groups with over 99% power using a two-sided 0.05 significance level 
to detect a standardized effect of 2 standard deviations. We anticipate 
a 15% attrition rate over the 9 month study period, so we expect 102 
participants, or 51 per randomization assignment, to complete the 
intervention and attend the final assessment.
Participants will be randomized to treatments in blocks of size 
2. Blocks will be formed based on body mass index (27-34.9 and 35-
45 kg/m2) and cancer stage (i.e. stage 1, 2, or 3). To account for pre-
randomization drops (i.e., screening failures and PI withdrawals) and 
an anticipated 15-20% attrition rate during the intervention and follow 
up periods, up to 220 participants will be consented and screened. This 
should provide for 102 participants at study completion. Participants 
will be randomized at their second screening visit if they continue to 
meet the study criteria. Reasons for exclusion will be recorded and 
reported as these exclusion criteria may provide additional insight 
into the barriers breast cancer survivors experience when seeking 
assistance with weight loss and making lifestyle changes. Participants 
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 Screening Randomization/Baseline (Month 0) Post-intervention (Month 3) Follow-up (Month 9)
Body weight X X X X
Height X    
Blood pressure X  X X
Lipids/inflammatory markers (venous sample)  X X X
HgA1c  X X X
Fasting glucose  X X X
Dietary intake (ASA-24) X  X X
Body composition  X X X
Waist circumference  X X X
Sagittal abdominal diameter  X X X
Accelerometry  X X X
IPAQ  X X X
QLQ-30 and BR-23  X X X
WEL  X X X
WMQ  X X
Program Evaluation  X X
•	 Body weight: Assessed using the Seca digital scale.
•	 Height: Assessed using a digital wall mounted stadiometer (Heightronic 235). 
•	 Blood pressure: Systolic and diastolic blood pressure will be assessed at each time point using an appropriately sized cuff and after the participant has been 
sitting quietly for at least 10 minutes. Blood pressure is consistently measured on the left arm of each participant, unless they have experienced lymphedema or 
other side effects of breast cancer/breast cancer treatment, making the right arm a better choice for blood pressure assessment.
•	 Waist circumference: Waist circumference will be measured in triplicate at the top of the iliac crest using a tension controlled tape measure upon exhalation.
•	 Sagittal abdominal diameter: Sagittal abdominal diameter will be measured in triplicate using a Holtain Kahn caliper at the top of the iliac crest upon exhalation.
•	 Body composition: Change in fat and fat free mass will be determined by air displacement plethysmography (Bodpod, COSMED, Inc). 
•	 Lipids, HgA1c, glucose and inflammatory/metabolic disease biomarkers:  A phlebotomist will take a 45 ml (3 tbsp) sample of arterial blood to assess total 
cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, HgA1c, glucose, and circulating soluble and cellular factors associated with inflammation and cancer 
biology (i.e., CRP, estrogen, etc) (Table 2).
Table 1: Participant assessment plan.
who experience cancer recurrence or a new cancer diagnosis will be 
removed prior to data analysis.
The statistical analysis for the primary end-point will be done by 
Student’s t-test to determine the difference between groups for the 
weight loss between TLI and CWLP groups (adjusted for age and 
gender) assuming a normal distribution of the results. The secondary 
endpoints 1) changes in inflammation/chronic disease markers and 
2) changes in health related quality of life and self-efficacy within this 
population will be assessed using analysis of covariance (ANCOVA) 
using the baseline values as covariates (i.e. baseline LDL-cholesterol). 
Additionally, we will compare the effect of weight loss on changes in 
inflammation/chronic disease markers assessed by ANCOVA.
Discussion
Excess adiposity is a modifiable risk factor for breast cancer 
development. In addition, obesity is associated with multiple co-
morbidities and increased recurrence in breast cancer survivors. 
While this association is well accepted, the impact of losing weight and 
weight loss maintenance in breast cancer survivors is unknown [44]. 
Therefore, this randomized, multicenter clinical trial will examine the 
effectiveness of a tailored lifestyle intervention compared to a standard 
commercial weight loss program on the specific high-risk population 
of overweight/obese breast cancer patients. This study serves to add to 
the dearth of literature regarding the impact of weight loss on markers 
of systemic inflammation that are associated with recurrence of breast 
cancer.
Epidemiologic and observational studies have found inconsistent 
findings on the best dietary pattern to reduce the risk for breast cancer 
risk and development. In addition, a few randomized clinical trials have 
tested low fat diets on both the incidence and the recurrence of breast 
cancer again with conflicting results. For instance, Prentice et al., [45] 
found a prescribed dietary plan limiting total fat intake to 20% of total 
calories and increasing fruit, vegetable and grains in post-menopausal 
women did not reduce the risk for development of invasive breast 
cancer over an approximate 8 year follow-up period. Similarly, Pierce 
et al. showed that [46] a diet high in fruit, vegetables, and fiber and low 
in fat did not prevent breast cancer recurrence or death in women with 
early stage breast cancer after an approximate seven-year follow-up. 
On the other hand, Chlebowski et al., [47] found that a low fat diet with 
a moderate weight loss prevented relapse of breast cancer in women 
receiving treatment for breast cancer, particularly those with estrogen 
negative tumors. While promising, the primary aim of this study was to 
test the effect of a low fat diet on breast cancer recurrence, not weight 
loss. While the primary aim of MyLIFE is to compare the effectiveness 
of two different interventions (TLI versus CWLP) on weight loss 
and weight maintenance our outcomes will also contribute to our 
understanding of how varying eating patterns and weight loss impact 
Thus, the primary aim of MyLIFE is to evaluate the effect of weight loss 
on markers of inflammation associated with breast cancer recurrence 
with secondary analyses including eating patterns. 
The study design presented here is unique in that focus groups will 
be conducted prior to beginning the intervention in order to tailor the 
program specifically to survivors of breast cancer. Not only will the 
focus groups be conducted with survivors, but also with health care 
providers that are integral to their care including breast surgeons, 
RDNs, nurses, case workers, psychologists, and physical therapists. The 
feedback from these focus groups will be used to guide the development 
of the motivational group sessions. Topics will include barriers to 
losing weight, social support, self-image, and items necessary to create 
the most enabling intervention specifically geared to this group. Given 
the challenges of long-term weight loss maintenance in the general 
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population and the additional challenges of having been treated for 
breast cancer, we believe this tailored approach will lead to more robust 
and more sustained changes than a conventional weight loss program. 
While being overweight contributes to a 30% increase in a women’s 
risk in developing breast cancer, additional studies have shown that 
physical activity contributes to an approximately 30% decrease in 
breast cancer risk mortality. With that said, few interventions have 
examined the impact of the combination of these two factors: reducing 
obesity and increasing physical activity in the development and 
prognosis of breast cancer [18]. Muhammadi et al., [48] completed a 
cross sectional analysis of Iranian breast cancer survivors and found an 
association between better eating habits and more physical activity, and 
greater perceived quality of life. The findings of this study indicate that 
breast cancer survivors can have an improved quality of life through 
attention to nutrition and physical activity. The behavioral intervention 
presented here will include a tailored approach to not only improving 
dietary choices, but also increasing physical activity, thus addressing 
the need for more randomized clinical trials to test the impact of both 
weight loss and increasing physical activity on the risk of breast cancer 
recurrence.
After the 13-week intervention proposed, the authors expect to see 
a 9% body weight loss in the TLI. Although CWLP participants are 
likely to also experience a degree of weight loss, the authors anticipate 
that mean weight losses will be greater among the TLI participants, 
as this intervention will address specific barriers to healthy eating, 
exercise and weight control that arise in this population. In addition 
to the primary outcome of weight reduction, cancer and systemic 
inflammatory markers will be measured prior to beginning the study, at 
the end of the intervention, and at the 6-month follow-up assessment. 
As previously mentioned, obesity is associated with the development of 
multiple systemic and metabolic disease whereby physical inactivity is 
a major contributor to the development [49]. Furthermore, it is known 
that regular exercise prevents or at least delays the onset of many of 
these complications independent of weight loss [50]. Multiple studies 
have identified inflammation as a key association between obesity 
and the development of these chronic diseases, including cancer [49]. 
Importantly, exercise and loss of adipose tissue promotes numerous 
molecular and cellular changes which negatively affect inflammation 
and positively affect immunoregulation [49]. Thus, we propose that if 
participants are successful in making weight-related lifestyle changes, 
they should experience a decrease in chronic systemic inflammation 
which in turn may result in a reduced risk of breast cancer recurrence. 
There are, however, challenges this trial is likely to face. Specifically, 
our basis for comparing the TLI to CWLP is that breast cancer survivors 
have unique and potentially additional barriers to making sustained 
lifestyle changes compared with women who have never experienced 
breast cancer. Thus, we predict that helping the women overcome these 
barriers will be more difficult than when working with overweight, yet 
healthy, adults. The first phase of this project is meant to allow us to 
Biomarkers Relevance to Breast Cancer and Obesity
TNFα Pro-inflammatory cytokine that is increased in with obesity and plays a role in all steps of tumorigenesis [22]
Insulin High levels of insulin are positively associated with obesity, increased expression of leptin and leptin receptors in some breast cancers [23-25]
Leptin Promotes cell growth and proliferation in breast cancer [26,27]
IL6 Pro-inflammatory cytokine secreted by adipose tissue which induces cell proliferation/survival and angiogenesis; used as a prognostic tool associated with poor survival [28-30]
C-Reactive Protein Elevated levels are associated with obesity and decreased survival of breast cancer patients [31,32]
SHBG Decreases the amount of bioavailable estradiol and is negatively associated with obesity [33,34]
Adiponectin Low levels in obesity result in insulin resistance [35].
Estradiol The most active plasma estrogen which is elevated in obesity and strongly correlates with breast cancer risk [36,37]
VEGF Can be induced by leptin, causes angiogenesis and elevated levels are associated with increased adiposity [38,39]
Table 2: Biomarkers to be assessed prior to, after intervention the 3 month intervention period and at follow-up
•	 Dietary intake: Changes in food intake will be assessed using the National Cancer Institute’s Automated Self-Administered 24-hour recall system (ASA-24) [36]. 
The ASA-24 is free to researchers and requires Internet access. It uses a validated 3-pass method to evaluate food intake in the previous 24 hour period. Data 
are analyzed using the USDA Nutrient Database for food group, nutrient, and energy intake.   At the screening visit, participants will be given instructions on how 
to complete the recalls and be asked to have these completed prior to their randomization visit.  
•	 Change in medical status:  Completed by study staff using Medical Update form.
•	 Physical activity: Energy expenditure will be assessed using both objective measurement (via triaxial accelerometer) and subjective assessment (via the 
International Physical Activity Questionnaire, or IPAQ) [40]. To objectively determine energy expenditure and change in purposeful physical activity, participants 
will wear a triaxial accelerometer (Sensewear Armband, Bodymedia, Inc.) on their upper left arm (unless contraindicated by complications due to breast cancer/
breast cancer treatment) for 7 days prior to beginning the intervention, upon completing the 12-week intervention, and prior to completing their final assessment 
visit. Participants will also complete the IPAQ. The IPAQ is a 27-item self-report questionnaire that assesses physical activity in five activity domains (job-related, 
transportation, housework/house maintenance/caring for family, recreation/sport/leisure time, and time spent sitting). Comparisons of the IPAQ to activity monitor 
suggests that the results are roughly comparable for total physical activity (r=.55) and vigorous physical activity (r=.71), but less comparable for moderate physical 
activity (r =.21) [40].
•	 Health-related quality of life: Health-related quality of life will be assessed using the European Organization of Research and Treatment of Cancer – Quality 
of Life (QLQ-30) and the breast-cancer specific addendum (BR-23). The QLQ-30 is a 30-item self-report measure that assesses five functional scales (physical, 
role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea/vomiting) and one global health and quality of life scale. A study of the 
measure’s psychometric properties supported the hypothesized scale structure of the measure (all Cronbach’s alpha coefficients ≥ .70 except for “role functioning” 
which is X) [41]. The BR-23 is a 23-item self-report addendum that contains five subscales which assess aspects of quality of life specific to breast cancer. The 
measure has sufficient internal consistency (Cronbach’s alphas ranging from .70 to .90 in the United States [42]).
•	 Self-efficacy: Participants’ self-efficacy to abstain from eating in a variety of situations will be assessed using the Weight Efficacy Lifestyle (WEL) questionnaire. 
The WEL is a 20-item self-report measure containing five subscales assessing self-efficacy to abstain from eating when 1) experiencing negative emotions, 2) 
food is readily available, 3) experiencing social pressure to eat, 4) experiencing physical pain/discomfort, and 5) engaging in positive/enjoyable activities.  The 
five subscales have adequate internal consistency (Cronbach’s alpha values ranging from 0.70 to 0.90) as well as significant correlation with each other (r-values 
ranging from .39 to .66), which suggests that there is a global construct of weight self-efficacy [43].
•	 Weight Management Strategies:  The frequency of participants’ utilization of specific weight management strategies will be assessed using the Weight 
Management Questionnaire (WMQ). The WMQ was developed internally and there are currently no published data on the measure’s validity or reliability. 
Examples of strategies that are assessed include frequency of self-weighing, self-monitoring of food intake and physical activity, meal planning, and decreasing 
portion sizes.
Program Evaluation:  This brief measure assesses participants’ views about the degree to which they found various aspects of the program to be useful/helpful. 
Examples of program aspects to be evaluated include study materials, effectiveness of the group leader, and meeting facilities.
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identify many of these potentially unique barriers while the second 
phase of the project will allow us address these obstacles through the 
intervention structure itself rather than as they arise. We feel this 
approach will lead to greater sustained weight and behavior outcomes 
in this unique population. 
Thus, due to the number of confounding factors our platform 
addressed, we feel the tailored lifestyle intervention and its application 
presented here can serve as a platform to develop tailored lifestyle 
interventions for other high-risk populations.
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